AAV-Gcase D15 / Lysogene, Weizmann Institute of Science - LARVOL DELTA

Lysogene Reports Full Year 2020 Financial Results and Provides Operational Update (Businesswire) - "...Lysogene has entered into a collaborative research agreement with Yeda...aim of developing a novel AAV gene therapy approach for neuronopathic Gaucher disease, Parkinson’s disease, and other diseases associated with mutations in the GBA1 gene. Initial results are expected by Q1 2022."

Clinical data • CNS Disorders • Gaucher Disease • Parkinson's Disease